Sort
4,870 grants matching “glp 1”
Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly
$813,511Pere Puigserver · Dana-Farber Cancer Inst · R01 · FY2025 · DK
Optimization of Lead BKIs for Cryptosporidiosis Therapy
$813,238Wesley C Van Voorhis · University Of Washington · R01 · FY2025 · AI
Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase II
$812,615Peter M. Pushko · Medigen, Inc. · R44 · FY2017 · AI
Translational Research for Retinal Degeneration Therapies
$812,265Gustavo David Aguirre · University Of Pennsylvania · R01 · FY2008 · EY
Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase II
$811,565Peter M. Pushko · Medigen, Inc. · R44 · FY2016 · AI
Clinical Translation of Near Infrared Nerve-Specific Fluorophores for Nerve-sparing Prostatectomy
$810,809Connor William Barth · Trace Biosciences Inc · R44 · FY2024 · CA
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur
$810,596Garry John Southan · Radikal Therapeutics, Inc. · U01 · FY2015 · ES
Nano-scale proteomic analysis: development, implementation, and applications
$810,420Jinqiu Chen · Division Of Basic Sciences - Nci · ZIC · FY2018 · CA
TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure
$810,416Laurie E Sower · Chrysalis Biotherapeutics, Inc. · R44 · FY2013 · AI
STTR Phase II: Advance Early Detection of Lupus Nephritis with ClearGold
$809,923Mengxiao Yu · Clearnano, Inc. · R42 · FY2021 · DK
Optimization of Lead BKIs for Cryptosporidiosis Therapy
$809,679Wesley C Van Voorhis · University Of Washington · R01 · FY2022 · AI
Suction Device for Control and Accuracy of Transseptal Access
$808,638George A Mansfield · 3dt Holdings, Llc · R44 · FY2017 · HL
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
$807,794John N Van Den Anker · Children'S Research Institute · U54 · FY2015 · HD
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
$807,792John N Van Den Anker · Children'S Research Institute · U54 · FY2012 · HD
Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a
$807,362David Jackson · Ceria Therapeutics, Inc. · R44 · FY2023 · HL
Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency
$806,879Tomi K Sawyer · Courage Therapeutics, Inc. · R42 · FY2022 · DK
Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease
$806,673Pazhani Sundaram · Recombinant Technologies, Llc · R44 · FY2023 · AG
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease
$805,761James Cardelli · Oleolive, Inc. · R42 · FY2023 · AG
Project 1 - Profectus Biosciences, Inc.
$805,740John H Eldridge · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2019 · AI
Targeting FSH for the Therapy of Osteoporosis, Obesity and Neurodegeneration
$804,105Mone Zaidi · Icahn School Of Medicine At Mount Sinai · U19 · FY2024 · AG
Optimization of Lead BKIs for Cryptosporidiosis Therapy
$803,979Wesley C Van Voorhis · University Of Washington · R01 · FY2023 · AI
Optimization of Lead BKIs for Cryptosporidiosis Therapy
$803,939Wesley C Van Voorhis · University Of Washington · R01 · FY2024 · AI
Modulation of Insulin Signaling in Adipocytes
$803,748Philipp E Scherer · Ut Southwestern Medical Center · R01 · FY2025 · DK
Pathogenic mechanisms of obesity and its cardiometabolic complications
$802,843Nicola Santoro · Yale University · R01 · FY2025 · DK
From Evidence to Policy: Tailoring GLP-1RA Coverage for Optimal Health Outcomes
$802,363Hui Shao · Emory University · R01 · FY2025 · DK